Drug Profile


Alternative Names: AXD-455; CN-1493; CNI 1493; CPSI-2364; Semapimod salt

Latest Information Update: 30 Aug 2012

Price : $50

At a glance

  • Originator Picower Institute for Medical Research
  • Developer Cytokine PharmaSciences; GPC Biotech AG
  • Class Anti-inflammatories; Hydrazones; Small molecules
  • Mechanism of Action Cytokine inhibitors; HIV replication inhibitors; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Nitric oxide inhibitors; Raf kinase inhibitors; RNA inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation
  • Discontinued Chemoprotection; Crohn's disease; HIV infections; Pancreatitis; Psoriasis

Most Recent Events

  • 20 Oct 2011 Cytokine PharmaSciences has been acquired by Ferring Pharmaceuticals
  • 27 Jan 2011 Semapimod is still available for licensing as of 27 Jan 2011.
  • 30 Nov 2009 Adverse events data from a Phase-I trial in Inflammation and Autoimmune disorders released by Cytokine PharmaSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top